Immunic, Inc.
IMUX
$15.37
-$0.04-0.26%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 43.78% | 6.08% | 37.30% | 27.23% | 2.86% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 23.90% | -8.99% | 1.04% | 18.71% | 12.33% |
| Operating Income | -23.90% | 8.99% | -1.04% | -18.71% | -12.33% |
| Income Before Tax | -27.93% | 23.34% | -4.97% | -25.44% | 13.90% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -27.93% | 23.34% | -4.97% | -25.44% | 13.90% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -27.93% | 23.34% | -4.97% | -25.44% | 13.90% |
| EBIT | -23.90% | 8.99% | -1.04% | -18.71% | -12.33% |
| EBITDA | -23.97% | 9.03% | -1.05% | -18.68% | -12.27% |
| EPS Basic | 99.96% | 60.27% | 45.17% | -28.78% | 17.33% |
| Normalized Basic EPS | 99.96% | 63.77% | 45.18% | -28.78% | 1.34% |
| EPS Diluted | 99.96% | 60.27% | 45.17% | -28.78% | 17.33% |
| Normalized Diluted EPS | 99.96% | 63.77% | 45.18% | -28.78% | 1.34% |
| Average Basic Shares Outstanding | 297,266.63% | 92.96% | 91.46% | -2.59% | 4.16% |
| Average Diluted Shares Outstanding | 297,266.63% | 92.96% | 91.46% | -2.59% | 4.16% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |